Merck PsA

Safety and efficacy of tulisokibart in PsA

(Recruiting soon)

Type

Interventional - treatment

Purpose

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with substantial fatigue, pain, joint stiffness, and diminished function. The primary goal of PsA treatment is to control symptoms, prevent long-term damage, and normalize functioning, but certain therapies are known to be effective in only certain symptoms of the disease. Tulisokibart is a new type of treatment targeting TL1A, which may be an important actor in dysregulation of the immune system. 

The purpose of this study is to test the safety and efficacy of tulisokibart across many different symptoms of PsA. 

Eligibility

You may be eligible for this study if you:

• Are aged ≥18;
• Have been diagnosed with psoriatic arthritis; and
• Have active disease, ready to try a new therapy.

Participation

Participants will be randomized to receive either tulisokibart (testing three different doses) or placebo for the first 16 weeks. After 16 weeks, those in the initial placebo arm will be moved onto active treatment for an additional 40 weeks. An optional extension may allow participation for up to 2.5 years. 

You will be followed over the course of 1 year (and up to 2.5 years), with visits (including physical exam, blood draw, questionnaires, and drug administration) approximately every 4 weeks. 

You will receive compensation for your time at the study visits.